Blog — FEATURED NEWS Home — Back Bay Life Science Advisors

Posts in Blog

Investment Banking Update: Notable March Transactions and Cautious Optimism Ahead

BlogInvestment Banking TeamApril 3, 2023Investment Banking, Capital, Markets, Investing, Biotech, Medtech

The Transactional Landscape Of ADCs: A Payday for Payloads

BlogBack Bay Life Science AdvisorsMarch 2, 2023Capital, Biotech, M&A, Oncology, Transactions, Deal Landscape, Small Molecule Therapeutics

Healthcare Companies Venture Back into Public Markets

BlogInvestment Banking TeamFebruary 27, 2023Investment Banking, Capital, Markets, Investing, Biotech, Medtech

Proving the Promise of Gene Replacement and Editing in Treatment of Inherited Blood Diseases

BlogBack Bay Life Science AdvisorsFebruary 24, 2023Capital, Biotech, Cell therapy, Cell and Gene

2023: A Year for NASH Revival?

BlogBack Bay Life Science AdvisorsJanuary 23, 2023NASH, Liver, Biotech, Life Sciences Development, Partnering, Investment

Prepare for What the Markets Could Bring

BlogInvestment Banking TeamJanuary 18, 2023Investment Banking, Capital, Markets, Investing, Biotech, Medtech

The Year of US-Nordic Collaboration

2022 was the year of US-Nordic Collaboration for Back Bay Life Science Advisors

BlogBack Bay Life Science AdvisorsJanuary 10, 2023Jonathan Gertler

Inefficient Markets: Public Market Dislocations and Negative Biotech Enterprise Values

BlogInvestment Banking TeamMay 31, 2022BioPharma, IPO, Investing

Biopharma Companies Don’t Need to Be Public to Survive

BlogInvestment Banking TeamApril 14, 2022BioPharma, IPO, Investing

Back Bay in Cell & Gene: Shining Light on the Commercial Potential of Optogenetic Therapies

Back Bay Life Science Advisors examines the commercial and clinical potential of optogenetic therapies from ophthalmology diseases, and oncology to chronic pain and more.

BlogBack Bay Life Science AdvisorsFebruary 3, 2022Neurology, Optogenetics, Oncology

With Biotech Public Valuations Down, Look to Alternative Strategies to Enhance Company Value

BlogBack Bay Life Science AdvisorsJanuary 31, 2022Valuation, Investment, M&A, Investment Banking

Investment Banking Spotlight: GE, Johnson & Johnson, Philips, Siemens: Restructurings = Accelerating Focus and Investment

BlogInvestment Banking TeamDecember 14, 2021Investment Banking, Restructuring, Life Science Financing

Outsourced Pharma: The Pharmacological Treatment Pipeline For Traumatic Brain Injury

BlogBack Bay Life Science AdvisorsDecember 13, 2021Pharmaceutical Development, Neurology, Drug Pipeline, FDA

Companies and Themes to Watch at ASH 2021

BlogBack Bay Life Science AdvisorsDecember 9, 2021Cell Therapy, Oncology, hematology, Blood

The BioInnovation Institute Announces Partnership with Back Bay Life Science Advisors

BlogBack Bay Life Science AdvisorsJanuary 28, 2021Emerging BioPharma, Denmark, Cross-border

Analysis Of The Non-Alcoholic Steatohepatitis Drug Pipeline & Market

Blog, White PaperBack Bay Life Science AdvisorsDecember 15, 2020NASH, Drug Development, Clinical Stage

ASH 2020 Preview

Blog, EventsBack Bay Life Science AdvisorsNovember 30, 2020Cell Therapy, Oncology, hematology

ISD Immunotech, a Novo Seeds Portfolio Company, Enters Strategic Research Collaboration for the Development of a Novel Lupus Treatment [Back Bay Transaction]

BlogInvestment Banking TeamNovember 23, 2020Biogen, Lupus, Novo, Transactions

2020 IPO Class Performance

Investment Banking Update, BlogBack Bay Life Science AdvisorsSeptember 23, 2020Biotech Financing, IPOs, Biotech, Investment Banking

Integrating Patient Reported Outcomes

BlogBack Bay Life Science AdvisorsJanuary 2, 2020Clinical and Regulatory Affairs